Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors

Radiation Oncology

Table 2 Clinical and treatment-related information for patients with high-risk embryonal central nervous system tumors

	Patient no.	Sex	Age at diagnosis (years)	Primary tumor site	M stage	Extent of initial surgery in primary site	Age at the start of RT (years)	CSI dose (Gy)	Boost dose (Gy)	Administration of HDC + ASCT before RT	Maintenance therapy before RT	Status before RT	Follow-up time from diagnosis (months)	Disease progression after RT	Age at the last assessment (years)	Status	Initial height (SDS)	Latest height (SDS)	Hypothyroidism	Ototoxicity (Brock grade)	Initial FSIQ	Latest FSIQ
Medulloblastoma
	10	M	1.9	I	M0	GTR	2.3	18	54	Yes	–	PD^†	28	LR	4.3	DOD	NE	NE	NE	0	NE	NE
	11	M	2.7	I	M0	non-GTR	3.3	18	50.4	Yes	–	CR	109	–	11.8	NED	-0.3	-1.8	–	0	NE	95
	12	M	6.3	I	M1	GTR	6.4	31	54	No	–	CR	92	–	13.9	NED	0	-1.5	Subclinical	0	88	86
	13	F	8.1	I	M3	GTR	8.8	36	54	Yes	–	CR	23	–	10.0	NED	0	-0.7	NE	0	NE	96
	14	F	10.2	I	M0	non-GTR	10.9	23	55.8	Yes	–	PR^‡	109	–	19.3	SD	+0.5	-1.6	Subclinical	4	101	82
	15	M	10.3	I	M0	non-GTR	11.0	23	54	Yes	–	CR	50	–	14.4	NED	-2.4	-4.1	Secondary	0	NE	79
	16	M	11.8	I	M1	GTR	13.5	23	54	Yes	–	CR	83	–	19.8	NED	+0.4	-0.7	–	0	102	NE
sPNET
	17	M	2.3	S	M0	GTR	3.0	18	54	Yes	CT, ICE	PD^†	28	LF	4.6	DOD	NE	NE	NE	NE	94	NE
	18	M	2.4	S	M0	GTR	3.3	18	54	Yes	CT	CR	92	–	10.1	NED	-0.5	-1.9	Subclinical	0	128	107
	19	F	2.4	S	M0	GTR	3.4	18	54	Yes	CT	CR	29	–	4.8	NED	+1.1	-0.1	Subclinical	NE	86	NE
	20	F	2.5	S	M0	Non-GTR	3.8	18	54	No	CT	CR	66	–	8.0	NED	-0.9	-2.4	–	NE	72	77
AT/RT
	21	M	0.3	I	M3	GTR	1.5	30	51	Yes	–	CR	71	LR	6.3	DOD	-1.0	-4.8	NE	2	NE	NE
	22	F	1.3	S	M0	Non-GTR	2.6	18	54	Yes	IFNß	CR	118		11.2	NED	-0.4	-1.1	Subclinical	2	75	62
	23	M	2.8	I	M3	Non-GTR	3.3	31	39.6*	Yes	–	PR^§	46	LR	6.7	DOD	NE	NE	NE	0	102	88
Pineoblastoma
	24	M	1.3	S	M3	Non-GTR	2.3	30	49.8	Yes	CT, MTX	PD^¶	19	LR	2.8	DOD	NE	NE	NE	NE	NE	NE

Abbreviations: ASCT autologous stem-cell transplantation, AT/RT atypical teratoid/rhabdoid tumor, CR complete response, CSI craniospinal irradiation, CT cyclophosphamide and topotecan, DOD death of disease, FSIQ full-scale intelligence, GTR gross total resection, HDC high-dose chemotherapy, I infratentorial, ICE ifosfamide, carboplatin and etoposide, IFN interferon, LF local failure, LR leptomeningeal recurrence, MTX methotrexate, NE not evaluated, NED no evidence of disease, PD progression disease, PR Partial response, RT radiation therapy, S supratentorial, SD stable disease, SDS standard deviation score, sPNET supratentorial primitive ectodermal tumor
*Boost RT was limited to spinal lesion of Th9-S2.
^†Local failure.
^‡Residual primary tumor.
^§Residual spinal seeding.
^¶Leptomeningeal recurrence.

ISSN: 1748-717X